MAZE — Maze Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Maze Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 99.9 | 29.2 | 197 | 342 |
| Prepaid Expenses | ||||
| Total Current Assets | 106 | 34.1 | 202 | 350 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 41.2 | 35 | 29.9 | 25.2 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 150 | 71.5 | 241 | 397 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 20.8 | 16.3 | 20.7 | 22.6 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 48.5 | 61.5 | 43.6 | 42.2 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Total Equity | 101 | 10.1 | 197 | 355 |
| Total Liabilities & Shareholders' Equity | 150 | 71.5 | 241 | 397 |
| Total Common Shares Outstanding | ||||
| Total Preferred Shares Outstanding |